Detection of prostate cancer using prostate-specific antigen adjusted for the transition zone volume in patients with intermediate serum prostate-specific antigen levels

Background. The prostate-specific antigen (PSA) density of the transition zone (PSATZ) in patients with PSA values of 4.1-10 ng/ml was determined to find whether PSATZ is useful in the detection of prostate cancer. Methods. The PSA, PSA density (PSAD), and PSATZ were determined in 101 patients with...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:International journal of clinical oncology 2000-08, Vol.5 (4), p.236-240
Hauptverfasser: Furuya, Y., Sato, N., Suzuki, K., Kotake, T., Masai, M.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 240
container_issue 4
container_start_page 236
container_title International journal of clinical oncology
container_volume 5
creator Furuya, Y.
Sato, N.
Suzuki, K.
Kotake, T.
Masai, M.
description Background. The prostate-specific antigen (PSA) density of the transition zone (PSATZ) in patients with PSA values of 4.1-10 ng/ml was determined to find whether PSATZ is useful in the detection of prostate cancer. Methods. The PSA, PSA density (PSAD), and PSATZ were determined in 101 patients with intermediate levels of serum PSA. The relationship of these parameters to prostate cancer detection was examined. Results. Patients with prostate cancer had significantly higher PSAD and PSATZ values than those without prostate cancer. In patients with a PSA value of 4.1-10 ng/ml, especially in those without abnormal digital rectal examination findings, PSATZ was superior to PSA as an indicator for positive biopsy when analyzed by receiver operating characteristics curves. In those patients with a cutoff value of 0.3 ng/ml per ml of transition zone volume, PSATZ had a sensitivity of 79% and a specificity of 51%. A cutoff value of 0.3 for PSATZ provided a sensitivity of 88% and a specificity of 51% in patients without abnormal digital rectal examination findings. Conclusion. The present study demonstrated that PSATZ was superior to PSA as an indicator for positive biopsy, especially in patients with normal digital rectal examination findings. PSATZ was not superior to PSAD in the detection of prostate cancer.[PUBLICATION ABSTRACT]
doi_str_mv 10.1007/PL00012043
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_1544857215</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3371487021</sourcerecordid><originalsourceid>FETCH-LOGICAL-c131t-9f03e9e049f38efd44d063598b7342603cb09a4d5f0cc79324fd9ce90fff8d1c3</originalsourceid><addsrcrecordid>eNp9kc1KxDAUhYMoOI5ufIKAO6GaNGnTLGX8hQFd6LpkkpuZDG1ak3RE38i3tOOI7lzdy-FwvgMHoVNKLigh4vJpTgihOeFsD00oZyITQuT74884zWSZF4foKMb1aBJlkU_Q5zUk0Ml1HncW96GLSSXAWnkNAQ_R-eWvmsUetLNOY-WTW4LHyqyHmMBg2wWcVoBTUD6677iPzgPedM3QAnYe9yo58CniN5dWo5AgtGDcFhYhDO0_lAY20MRjdGBVE-Hk507Ry-3N8-w-mz_ePcyu5pmmjKZMWsJAAuHSsgqs4dyQkhWyWgjG85IwvSBScVNYorWQLOfWSA2SWGsrQzWborNd7ljodYCY6nU3BD8ia1pwXhUip8XoOt-59Fg7BrB1H1yrwntNSb2dov6bgn0B6KaAfg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1544857215</pqid></control><display><type>article</type><title>Detection of prostate cancer using prostate-specific antigen adjusted for the transition zone volume in patients with intermediate serum prostate-specific antigen levels</title><source>Springer Online Journals Complete</source><creator>Furuya, Y. ; Sato, N. ; Suzuki, K. ; Kotake, T. ; Masai, M.</creator><creatorcontrib>Furuya, Y. ; Sato, N. ; Suzuki, K. ; Kotake, T. ; Masai, M.</creatorcontrib><description>Background. The prostate-specific antigen (PSA) density of the transition zone (PSATZ) in patients with PSA values of 4.1-10 ng/ml was determined to find whether PSATZ is useful in the detection of prostate cancer. Methods. The PSA, PSA density (PSAD), and PSATZ were determined in 101 patients with intermediate levels of serum PSA. The relationship of these parameters to prostate cancer detection was examined. Results. Patients with prostate cancer had significantly higher PSAD and PSATZ values than those without prostate cancer. In patients with a PSA value of 4.1-10 ng/ml, especially in those without abnormal digital rectal examination findings, PSATZ was superior to PSA as an indicator for positive biopsy when analyzed by receiver operating characteristics curves. In those patients with a cutoff value of 0.3 ng/ml per ml of transition zone volume, PSATZ had a sensitivity of 79% and a specificity of 51%. A cutoff value of 0.3 for PSATZ provided a sensitivity of 88% and a specificity of 51% in patients without abnormal digital rectal examination findings. Conclusion. The present study demonstrated that PSATZ was superior to PSA as an indicator for positive biopsy, especially in patients with normal digital rectal examination findings. PSATZ was not superior to PSAD in the detection of prostate cancer.[PUBLICATION ABSTRACT]</description><identifier>ISSN: 1341-9625</identifier><identifier>EISSN: 1437-7772</identifier><identifier>DOI: 10.1007/PL00012043</identifier><language>eng</language><publisher>Tokyo: Springer Nature B.V</publisher><subject>Medical research ; Prostate cancer</subject><ispartof>International journal of clinical oncology, 2000-08, Vol.5 (4), p.236-240</ispartof><rights>The Japan Society of Clinical Oncology 2000</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,781,785,27929,27930</link.rule.ids></links><search><creatorcontrib>Furuya, Y.</creatorcontrib><creatorcontrib>Sato, N.</creatorcontrib><creatorcontrib>Suzuki, K.</creatorcontrib><creatorcontrib>Kotake, T.</creatorcontrib><creatorcontrib>Masai, M.</creatorcontrib><title>Detection of prostate cancer using prostate-specific antigen adjusted for the transition zone volume in patients with intermediate serum prostate-specific antigen levels</title><title>International journal of clinical oncology</title><description>Background. The prostate-specific antigen (PSA) density of the transition zone (PSATZ) in patients with PSA values of 4.1-10 ng/ml was determined to find whether PSATZ is useful in the detection of prostate cancer. Methods. The PSA, PSA density (PSAD), and PSATZ were determined in 101 patients with intermediate levels of serum PSA. The relationship of these parameters to prostate cancer detection was examined. Results. Patients with prostate cancer had significantly higher PSAD and PSATZ values than those without prostate cancer. In patients with a PSA value of 4.1-10 ng/ml, especially in those without abnormal digital rectal examination findings, PSATZ was superior to PSA as an indicator for positive biopsy when analyzed by receiver operating characteristics curves. In those patients with a cutoff value of 0.3 ng/ml per ml of transition zone volume, PSATZ had a sensitivity of 79% and a specificity of 51%. A cutoff value of 0.3 for PSATZ provided a sensitivity of 88% and a specificity of 51% in patients without abnormal digital rectal examination findings. Conclusion. The present study demonstrated that PSATZ was superior to PSA as an indicator for positive biopsy, especially in patients with normal digital rectal examination findings. PSATZ was not superior to PSAD in the detection of prostate cancer.[PUBLICATION ABSTRACT]</description><subject>Medical research</subject><subject>Prostate cancer</subject><issn>1341-9625</issn><issn>1437-7772</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2000</creationdate><recordtype>article</recordtype><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNp9kc1KxDAUhYMoOI5ufIKAO6GaNGnTLGX8hQFd6LpkkpuZDG1ak3RE38i3tOOI7lzdy-FwvgMHoVNKLigh4vJpTgihOeFsD00oZyITQuT74884zWSZF4foKMb1aBJlkU_Q5zUk0Ml1HncW96GLSSXAWnkNAQ_R-eWvmsUetLNOY-WTW4LHyqyHmMBg2wWcVoBTUD6677iPzgPedM3QAnYe9yo58CniN5dWo5AgtGDcFhYhDO0_lAY20MRjdGBVE-Hk507Ry-3N8-w-mz_ePcyu5pmmjKZMWsJAAuHSsgqs4dyQkhWyWgjG85IwvSBScVNYorWQLOfWSA2SWGsrQzWborNd7ljodYCY6nU3BD8ia1pwXhUip8XoOt-59Fg7BrB1H1yrwntNSb2dov6bgn0B6KaAfg</recordid><startdate>20000825</startdate><enddate>20000825</enddate><creator>Furuya, Y.</creator><creator>Sato, N.</creator><creator>Suzuki, K.</creator><creator>Kotake, T.</creator><creator>Masai, M.</creator><general>Springer Nature B.V</general><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope></search><sort><creationdate>20000825</creationdate><title>Detection of prostate cancer using prostate-specific antigen adjusted for the transition zone volume in patients with intermediate serum prostate-specific antigen levels</title><author>Furuya, Y. ; Sato, N. ; Suzuki, K. ; Kotake, T. ; Masai, M.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c131t-9f03e9e049f38efd44d063598b7342603cb09a4d5f0cc79324fd9ce90fff8d1c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2000</creationdate><topic>Medical research</topic><topic>Prostate cancer</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Furuya, Y.</creatorcontrib><creatorcontrib>Sato, N.</creatorcontrib><creatorcontrib>Suzuki, K.</creatorcontrib><creatorcontrib>Kotake, T.</creatorcontrib><creatorcontrib>Masai, M.</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><jtitle>International journal of clinical oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Furuya, Y.</au><au>Sato, N.</au><au>Suzuki, K.</au><au>Kotake, T.</au><au>Masai, M.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Detection of prostate cancer using prostate-specific antigen adjusted for the transition zone volume in patients with intermediate serum prostate-specific antigen levels</atitle><jtitle>International journal of clinical oncology</jtitle><date>2000-08-25</date><risdate>2000</risdate><volume>5</volume><issue>4</issue><spage>236</spage><epage>240</epage><pages>236-240</pages><issn>1341-9625</issn><eissn>1437-7772</eissn><abstract>Background. The prostate-specific antigen (PSA) density of the transition zone (PSATZ) in patients with PSA values of 4.1-10 ng/ml was determined to find whether PSATZ is useful in the detection of prostate cancer. Methods. The PSA, PSA density (PSAD), and PSATZ were determined in 101 patients with intermediate levels of serum PSA. The relationship of these parameters to prostate cancer detection was examined. Results. Patients with prostate cancer had significantly higher PSAD and PSATZ values than those without prostate cancer. In patients with a PSA value of 4.1-10 ng/ml, especially in those without abnormal digital rectal examination findings, PSATZ was superior to PSA as an indicator for positive biopsy when analyzed by receiver operating characteristics curves. In those patients with a cutoff value of 0.3 ng/ml per ml of transition zone volume, PSATZ had a sensitivity of 79% and a specificity of 51%. A cutoff value of 0.3 for PSATZ provided a sensitivity of 88% and a specificity of 51% in patients without abnormal digital rectal examination findings. Conclusion. The present study demonstrated that PSATZ was superior to PSA as an indicator for positive biopsy, especially in patients with normal digital rectal examination findings. PSATZ was not superior to PSAD in the detection of prostate cancer.[PUBLICATION ABSTRACT]</abstract><cop>Tokyo</cop><pub>Springer Nature B.V</pub><doi>10.1007/PL00012043</doi><tpages>5</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1341-9625
ispartof International journal of clinical oncology, 2000-08, Vol.5 (4), p.236-240
issn 1341-9625
1437-7772
language eng
recordid cdi_proquest_journals_1544857215
source Springer Online Journals Complete
subjects Medical research
Prostate cancer
title Detection of prostate cancer using prostate-specific antigen adjusted for the transition zone volume in patients with intermediate serum prostate-specific antigen levels
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-15T14%3A06%3A09IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Detection%20of%20prostate%20cancer%20using%20prostate-specific%20antigen%20adjusted%20for%20the%20transition%20zone%20volume%20in%20patients%20with%20intermediate%20serum%20prostate-specific%20antigen%20levels&rft.jtitle=International%20journal%20of%20clinical%20oncology&rft.au=Furuya,%20Y.&rft.date=2000-08-25&rft.volume=5&rft.issue=4&rft.spage=236&rft.epage=240&rft.pages=236-240&rft.issn=1341-9625&rft.eissn=1437-7772&rft_id=info:doi/10.1007/PL00012043&rft_dat=%3Cproquest_cross%3E3371487021%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1544857215&rft_id=info:pmid/&rfr_iscdi=true